Charged Alpha Stock Encyclopedia

Paycom (PAYC) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $531.2M vs $483.6M, +9.8%, against a ~$513.1M Street bar. Recurring and other revenue $505.2M, +11.0%, 95.1% of the total; interest on funds held for clients $26.0M vs $28.5M, DOWN 8.8%. GAAP net income $107.4M / $2.34 diluted EPS vs $89.5M / $1.58. Non-GAAP net income $127.7M / $2.78 diluted EPS vs $116.6M / $2.06, against a $2.28 consensus bar. Adjusted EBITDA $235.0M vs $198.3M, a 44.2% margin vs 41.0%. Diluted shares 45.9M vs 56.5M. FY2026 guidance RAISED: revenue $2.197-$2.212B (from $2.175-$2.195B) and adjusted EBITDA $1.007-$1.022B (from $950-$970M). The 8-K was accepted at 4:10 p.m. ET Wednesday Aug 5 (after the close); the stock closed Thursday Aug 6 at $215.97 vs $174.80, up 23.55%, and $214.99 on Friday Aug 7.

Paycom beat the bar by fifty cents - $2.78 non-GAAP against $2.28 - raised full-year guidance, and the stock added 23.55% in a single session. Then divide the very same profit by last year's share count and the number comes out at $2.26, which is UNDER the bar. Non-GAAP net income rose 9.5%, from $116.6M to $127.7M. Non-GAAP diluted EPS rose 35.0%, from $2.06 to $2.78. Everything between those two numbers is the denominator: diluted shares fell 18.8%, from 56.5 million to 45.9 million, because Paycom borrowed $900 million (long-term debt was ZERO on December 31) and retired 10.9 million shares in six months for $1.414 billion at an average price of $129.72 - 19.9% of the company. Of the 72 cents of year-over-year EPS growth, roughly 52 cents is share count and roughly 20 cents is the business. The second surprise: total R&D costs (expensed plus capitalized) fell from $111.7M to $67.6M, down 39.5% - 23.1% of revenue to 12.7%. The guidance raise reflects it. The adjusted EBITDA midpoint rose $54.5M on a revenue midpoint raise of only $19.5M, a 280% flow-through that cannot come from revenue.

THE CALL: HOLD (3/5, A REAL BEAT, MOSTLY BOUGHT - AND THE 23.6% POP ALREADY PAID YOU FOR THE RAISE) — base-case value ~$227.0 vs ~$214.99 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$227 vs the $214.99 Aug 7 close (+5.6%). Bull $309, base $234, bear $160. Street: Hold, 36 analysts, avg target $200.67 - BELOW the tape.

- Non-GAAP EPS $2.78 vs a $2.28 bar (+35.0%), but non-GAAP net income rose just 9.5% to $127.7M. Revenue $531.2M, +9.8%. Adj EBITDA $235.0M, margin 44.2% vs 41.0%.

- Diluted shares fell 18.8% to 45.9M. $127.7M on last year's 56.5M shares is $2.26 - UNDER the bar. FY26 EBITDA guide +$54.5M on a +$19.5M revenue raise.

What to watch: UP: a Q3 that holds the ~46% adjusted EBITDA margin without another cut to technology spend; recurring revenue accelerating above 11.0%; a Q4 guide above the implied 6%; 10-Q evidence that the R&D reduction is genuine automation-driven efficiency. DOWN: total R&D snapping back toward 16% of revenue; recurring growth slipping under 8%; the share count flattening because the stock is too expensive to retire; interest on funds held for clients guided down a fourth straight year.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Sempra (SRE) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): GAAP earnings $796M / $1.21 diluted EPS vs $461M / $0.71. Adjusted earnings $762M / $1.16 adjusted diluted EPS vs $583M / $0.89, against a Street bar of $1.07 - a $0.09 beat. Revenue $2,997M vs $3,000M, essentially flat, and 6.9% below the ~$3.22B consensus. Equity earnings $547M vs $393M. 2026 GAAP EPS guidance raised to $5.02-$5.55; 2026 adjusted EPS guidance only AFFIRMED at $4.80-$5.30; 2027 affirmed $5.10-$5.70; long-term growth 7-9%. Shares closed the print day (Aug 6) at $84.35, down 0.37%, and $84.56 on Aug 7.

Sempra beat the adjusted earnings bar by nine cents - $1.16 against $1.07 - and grew adjusted earnings 30% on revenue that was dead flat and missed consensus by about 7%. The stock closed DOWN 0.37% on 5.7M shares against a 3.6M average. Here is why, and it is one sentence in Sempra's own 10-Q that nobody quoted: 'In the second quarter of 2026, Oncor recognized the impact of the surcharge, including amounts related to the first quarter of 2026. As a result, our second-quarter equity earnings include a favorable impact of approximately $50 million, net of income tax, attributable to the first quarter.' Fifty million dollars across 655.9M diluted shares is $0.076 a share - eight cents of the nine-cent beat. Strip the out-of-period catch-up and Q2 adjusted EPS was about $1.08 against a $1.07 bar. An in-line quarter. We also tested the obvious cynical explanation - that the bar had been cut - by pulling the February and May 8-Ks off EDGAR. The 2026 adjusted range has been $4.80-$5.30 all year, unchanged, and the $1.07 quarterly bar demanded 20% year-over-year growth. That thesis is FALSE, and the falsification is the more useful finding. Our call is HOLD, 3/5, fair value ~$88 against the $84.56 close. Wall Street says Buy with an average target near $106 - and not one of the 26 analysts has a target at or below the price.

THE CALL: HOLD (3/5, A GOOD BUSINESS AT A FAIR PRICE, ON A QUARTER THAT DID NOT MAKE IT CHEAPER) — base-case value ~$88.0 vs ~$84.56 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$88 vs the $84.56 Aug 7 close (+4.1%). Bull $106, base $88, bear $66. Street: Buy, 26 analysts, avg target $106, median $103.50, LOW $101.

- Adjusted EPS $1.16 vs a $1.07 bar (+8.4%), adjusted earnings $762M vs $583M. GAAP EPS $1.21 vs $0.71. Revenue $2,997M, flat and 6.9% under the ~$3.22B bar.

- But the 10-Q says ~$50M of Q2 equity earnings ($0.08/sh) was attributable to Q1. Adjusted guidance only AFFIRMED at $4.80-$5.30; H1 is $2.67, so H2 implies -0.4%.

What to watch: UP: signed interconnection agreements out of Oncor's ~44 GW Batch Zero large-load queue; the 2026-2030 capital plan raised above $65B; the KKR close for 45% of Sempra Infrastructure landing above expectations; Q3 landing at the top of the $4.80-$5.30 band. DOWN: a California wildfire event that outruns the AB 1054 fund; an adverse 2028 California GRC; common equity issued to plug the funding gap; a Q3 that confirms the first half was borrowed.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Novo Nordisk A/S (NVO) Q2 2026 — Q2 2026 (quarter ended June 30, 2026), reported in Danish kroner: adjusted net sales DKK 78,488M, +7% at constant currency. Adjusted operating profit DKK 33,389M, +11% CER. Adjusted diluted EPS per ADR DKK 6.18 against a bar worth about DKK 5.01 - a 23% beat. IFRS diluted EPS was DKK 4.75, DOWN 20%; the gap is DKK 6,328M of non-cash pipeline impairments. FY2026 guidance was RAISED from -4%/-12% to 0%/-6% CER. Novo published at 07.00 ET on Aug 4, before the US open: NVO opened $47.59, ran to $49.15, and closed $44.28 - down 5.97% on 47.5M shares against a 14.9M average. It closed Aug 7 at $46.90.

Novo Nordisk beat the adjusted earnings bar by about 23% (DKK 6.18 vs roughly DKK 5.01), raised full-year guidance four points at both ends, and raised the free cash flow guide by DKK 9B - and the stock ran to $49.15 (+4.4%) then closed down 5.97% at $44.28 on triple volume. Four things nobody put on a slide. ONE: the raise is a raise of a DECLINE - guidance went from -4%/-12% to 0%/-6% CER, both ends still negative, and using Novo's own +5% CER non-adjusted midpoint the residual leaves H2 2026 at DKK 141,449M against H2 2025's DKK 153,922M, MINUS 8.1%. TWO: adjusted sales grew 6% in kroner and adjusted gross profit grew ZERO; margin went 82.7% to 78.2%, and the whole +11% CER profit growth came from cutting sales and distribution costs 13%. THREE: Wegovy pill is the best GLP-1 volume launch ever - 2.9M US scripts in the quarter - but DKK 3,218M over 2.9M scripts is about $170 a script, against a list price near $1,350 that halves to $675 on Jan 1, 2027. FOUR: H1 free cash flow was DKK 55.3B and the FULL-YEAR guide is DKK 45-55B, so the raised guide implies a second half between minus DKK 10B and roughly zero. We prove the EPS basis three ways. Fair value $38 vs $46.90 - and the Street's own MEDIAN target of $44.55 is already below the price.

THE CALL: AVOID (4/5, A GREAT FRANCHISE, REPRICING ITSELF IN PUBLIC) — base-case value ~$38.0 vs ~$46.9 today.

KEY METRICS:

- CALL: AVOID 4/5, fair value ~$38 vs the $46.90 Aug 7 close (-19%). Bull $61, base $34, bear $21. Street: Buy, 14 analysts, avg target $47.12, MEDIAN $44.55.

- Adjusted sales DKK 78,488M +7% CER. Adjusted EPS/ADR DKK 6.18 vs a ~DKK 5.01 bar (+23%). IFRS EPS DKK 4.75, -20%. Adjusted operating profit DKK 33,389M +11% CER.

- But adjusted gross profit grew 0% and margin fell to 78.2% from 82.7%. The raised guide still implies H2 -8%. H1 FCF DKK 55.3B vs a DKK 45-55B full-year guide.

What to watch: UP: Medicare Part D Bridge converting obesity into a reimbursed benefit at real prices; adjusted gross margin stabilising above 78%; Q3 landing at the top of the guide band; capex falling faster than the DKK 55B plan. DOWN: a Q3 sales decline confirming the implied -8% second half; the Jan 1 2027 US list-price cut to USD 675 landing without a volume offset; the flagged further ZEUS impairment; free cash flow confirming a second half near zero.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Insulet Corporation (PODD) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $801.7M +23.5% (+22.7% constant currency), which cleared the TOP of Insulet's own 20-22% guide. Adjusted EPS $1.66 +41.5% vs a $1.47 bar (+12.9% beat). GAAP EPS $1.37 - the $0.29 gap is recall warranty cost. Adjusted gross margin 72.9%, a company record. FY2026 adjusted EPS guidance was RAISED from more than 25% growth to more than 30%, while the FY2026 U.S. Omnipod revenue guide was CUT from 20-22% to 17-19%. The 8-K was accepted 7:04 a.m. ET on Aug 5 (before the open), so the reaction is in the tape: PODD fell from $166.82 to $133.26 on Aug 5, minus 20.1% in one session on 7.2M shares, setting the 12-month closing low. It closed Aug 7 at $140.12 - down 60.3% from the $352.82 high of Sep 9, 2025.

Insulet beat on revenue, beat the adjusted EPS bar by 12.9% ($1.66 vs $1.47), and RAISED its full-year adjusted EPS guidance from more than 25% growth to more than 30% - and the stock fell 20.1% in a single session to a 12-month low. The total company revenue guide was cut by exactly ONE percentage point (21-23% to 20-22% constant currency). One point cost a fifth of the company, so we went looking for what the market actually repriced. It was not 2026; it was the U.S. exit rate. The entire cut is U.S. Omnipod, guided down from 20-22% to 17-19% - while International was RAISED from 26-28% to 30-32%. Do the residual arithmetic nobody published: FY2025 U.S. Omnipod was $1,919.8M; guide that up 17-19% and 2026 lands at $2,246-$2,285M. The first half already did $1,059.7M and the Q3 guide of 14-16% on a $497.1M base gives about $570M. That leaves Q4 at $610-$658M against $567.8M last year - implied growth of just 7-16%, midpoint 11.7%, against a Q4 2025 that grew 28.0%. The cause, per management: type-2 patients churn inside the first 90 days, though past 90 days their retention converges on type 1. About two-thirds of the cut is that one cohort effect. Second angle: adjusted EPS rose 41.5% while H1 free cash flow FELL 36.6%, to $145.4M from $229.4M, with capex up 83.8% for a new Costa Rica plant and a $60-70M recall bill that leaves EPS but not the bank. Third: adjusted gross margin hit a record 72.9% (+320bp) but only 140bp reached operating margin because SG&A grew 33.8% against revenue's 23.5%. We are buyers anyway - at 21.4x earnings, 12.3x EBITDA and 0.5x net debt, the price embeds a far worse outcome than the guide. But it is cheap on earnings and NOT cheap on cash, and we say so.

THE CALL: BUY (3/5, THE MARKET REPRICED THE STORY, NOT THE BUSINESS) — base-case value ~$172.0 vs ~$140.12 today.

KEY METRICS:

- CALL: BUY 3/5, fair value ~$172 vs the $140.12 Aug 7 close (+22.8%). Bull $299, base $173, bear $102. Street: Buy, 50 analysts, avg target $185.18.

- Revenue $801.7M +23.5% (+22.7% cc), above its own guide. Adjusted EPS $1.66 vs a $1.47 bar (+12.9%), +41.5% YoY. GAAP EPS $1.37. Adj gross margin 72.9%, a record.

- But FY26 U.S. Omnipod guide CUT from 20-22% to 17-19% on type-2 90-day churn. H1 free cash flow $145.4M vs $229.4M, -36.6%. Implied Q4 U.S. growth only 7-16%.

What to watch: UP: 90-day type-2 retention improving in the Q3 print; free cash flow turning back up as Costa Rica capex rolls off; the Q4 U.S. number landing at the top of the implied 7-16% band; adjusted gross margin holding above 72%; International sustaining the raised 30-32% guide. DOWN: a THIRD voluntary medical device correction; another U.S. guidance cut in November; a 2027 guide below the mid-teens management flagged; free cash flow still falling once the plant is finished; competitive entrants (Medtronic, Tandem, Beta Bionics) taking share in 2027.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Elanco Animal Health (ELAN) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $1,368M +10% (+8% organic constant currency), adjusted EPS $0.34 +31% vs a $0.27 bar, GAAP EPS $0.11, adjusted EBITDA $288M +21% at a 21.2% margin. FY2026 guidance RAISED for the third straight quarter to $5.09-5.14B revenue and $1.10-$1.16 adjusted EPS. The 8-K was accepted 6:27 a.m. ET on Aug 5 (before the open), so the reaction is in the tape: ELAN opened at $27.08, ran to $27.98 intraday, closed $26.22, then fell 7.7% to $24.20 on Aug 6 and closed Aug 7 at $23.255 - minus 16.9% from the print-day high.

Elanco beat the adjusted EPS bar by 26% ($0.34 vs $0.27), raised full-year guidance for the third straight quarter, and cut its year-end net leverage target - and the stock is down 16.9% from its print-day high. We tested the obvious cynical explanation first and it is FALSE: this was not a beat against a cut bar. Elanco RAISED its own guide in May to $0.25-$0.28 and then cleared the top of that raised range by 21%. The problem is somewhere else, and it is in the cash flow statement. In 2025 Elanco reported $901M of adjusted EBITDA; operating cash flow was $560M and capex $276M, so free cash flow was $284M - 31 cents on the adjusted EBITDA dollar. H1 2026 converted at 33% ($622M adjusted EBITDA, $290M operating cash flow, $84M net capex, $206M free cash flow), with working capital consuming $239M in six months. Second, the celebrated deleveraging is a denominator story: net leverage went 3.6x to 3.1x, but hold EBITDA still and the debt reduction alone gives 3.51x while holding debt still and applying EBITDA growth gives 3.22x - 76% of the improvement was the denominator, and the 10-Q shows only $89M of long-term borrowings repaid against $3,944M of gross debt. Third, Elanco's own definition of innovation revenue says it 'does not include the expected impact of cannibalization on the base portfolio': innovation goes $892M to a $1.25B target (+$358M) while total organic growth is guided at 6-7% (about +$307M), so the non-innovation base is shrinking roughly $51M, or 1.3%. And 79% of adjusted EPS ($0.27 of $0.34) is amortisation add-back against R&D that was FLAT at $92M.

THE CALL: HOLD (3/5, A REAL BEAT, AND THE SELLOFF WAS STILL RIGHT) — base-case value ~$22.5 vs ~$23.255 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$22.50 vs the $23.255 Aug 7 close (-3.2%). Bull $28.75, base $20.30, bear $14.00. Street: Buy, 21 analysts, avg target $28.67.

- Revenue $1,368M +10%. Adjusted EPS $0.34 vs a $0.27 bar (+26%). GAAP EPS $0.11. Adjusted EBITDA $288M +21%. FY26 guide RAISED a third time to $1.10-1.16.

- But: FY2025 adjusted EBITDA $901M became $284M of free cash flow (31%). Deleveraging was 76% denominator - only $89M of debt repaid. Base shrinking 1.3%.

What to watch: UP: working capital actually releasing in Q3 or Q4 with free cash flow conversion clearing 50%; the non-innovation base stabilising instead of shrinking; net leverage under 3.0x before year end; Elanco Ascend savings showing up early in the margin. DOWN: a third straight half of working-capital drag; innovation revenue hitting its target while total organic growth misses; R&D staying flat at $92M a quarter against $139M of quarterly amortisation; a 2027 guide that leans on price rather than volume.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

W.W. Grainger (GWW) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): net sales $5,021M +10.3% (+13.7% daily organic constant currency), diluted EPS $12.01 +20.5% vs a ~$11.30 bar, operating margin 16.1% (+120bps). FY2026 guidance RAISED on every line, EPS to $45.50-$47.25. The 8-K was accepted 8:03 a.m. ET on Aug 4 (before the open), so the reaction is in the tape: GWW fell 5.16% that day, $1,371.25 to $1,300.45, and closed Aug 6 at $1,282.58.

Grainger beat by $0.71 and raised full-year guidance on sales, gross margin, operating margin, EPS, cash flow, buyback and both segment margins - and the stock fell 5.16%. One sentence in the release explains it: refunds recognized on IEEPA tariffs for directly imported products reduced cost of goods sold by $43 million, about 90bps of gross margin. After the 24.8% tax rate that is $32.3M, or $0.685 across 47.2M diluted shares. Strip it and Q2 EPS is $11.33 against a bar of $11.30 - a three-cent quarter. The CEO said it in his own release: 'core operating profitability was in line with expectations.' Ex-refund, gross margin rose 12bps rather than 100, and operating margin 33bps rather than 120. In High-Touch Solutions - 79% of sales - the $43M is 108bps of segment sales, more than the 80bps its gross margin expanded: ex-refund High-Touch gross margin FELL 27bps and operating margin FELL 41bps. The raise has the same shape: daily organic constant-currency growth guidance went up 150bps at the midpoint while operating margin guidance went up only 20, and the implied second-half operating margin is 15.6% against 16.4% delivered in the first half. Management runs price-cost NEUTRAL, so tariff dollars passed through inflate revenue and dilute margin percentage. The genuinely good news nobody covered: Endless Assortment grew operating earnings 31.5% to $121M at an 11.5% margin, already above the raised 10.4-10.8% full-year guide. And the CFO resigned the day before the print.

THE CALL: HOLD (3/5, A GREAT BUSINESS, AND THE PRICE ALREADY KNOWS IT) — base-case value ~$1110.0 vs ~$1282.58 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$1,110 vs the $1,282.58 Aug 6 close (-13.5%). Bull $1,290, base $1,110, bear $920. Street: Hold, 38 analysts, avg target $1,298.78.

- Sales $5,021M +10.3%. EPS $12.01 +20.5% vs ~$11.30. Op margin 16.1%. FCF $333M. FY26 guide RAISED to $19.4-19.7B and EPS $45.50-47.25.

- But: a $43M IEEPA tariff refund IS the beat (ex-refund EPS $11.33). High-Touch core op margin -41bps. Implied H2 op margin 15.6% vs 16.4% in H1.

What to watch: UP: Endless Assortment holding a segment operating margin above 11% for two more quarters; High-Touch core gross margin expanding once the refund is out of the base; second-half operating margin printing above 16%; a permanent CFO with a credible capital-allocation record. DOWN: Q3 operating margin at or below 15.2%; High-Touch core margin contracting again; accounts receivable outgrowing sales a third straight quarter; a Q4 guide that leans on price rather than volume.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Albemarle Corporation (ALB) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): net sales $1,743.3M, +31.1% y/y, vs a $1,606.9M bar (+8.5%). Adjusted diluted EPS $3.75 vs $3.20 (+17.2%). GAAP diluted EPS $3.52. Adjusted EBITDA $858.1M, +155%, a 49.2% margin. Energy Storage sales +$559.0M on volume +11.0% (59 to 65 kT LCE) and realized price +60.5% ($12.17 to $19.53/kg) - so ~$478M, 86%, is price. Incremental EBITDA margin 90%. FCF $638.3M. Net debt $245M, leverage 0.5x. Diluted shares 136.2M vs basic 118.0M (+15.5%). Print was AMC (8-K accepted 16:22 ET Aug 5); the stock closed $125.42 the next session, +5.54%.

Albemarle reported Q2 2026 after the close on August 5 and beat both lines: net sales $1,743.3M against a $1,606.9M bar, and adjusted diluted EPS of $3.75 against $3.20. Adjusted EBITDA more than doubled to $858.1M. The stock rose 5.54% to $125.42. But Albemarle discloses what most producers do not - both volume and realized price. Energy Storage added $559.0M of sales on volume up 11.0% (59 to 65 kilotons LCE) and realized price up 60.5% ($12.17 to $19.53 per kg LCE). Decompose it: the pure price effect is $434M, volume $73M, and the cross term $44M - so roughly $478M, 86% of the increase, is the lithium price rather than operations. The incremental EBITDA margin was 90%, which runs in reverse just as hard. And the widely-assumed Ketjen angle is backwards: there is no discontinued-operations presentation, the $95.0M loss on sale sits in the six-month column with a dash in the three-month column, and the deconsolidation is a $218M HEADWIND to the y/y comparison, not a tailwind. Strip Ketjen from both years and the continuing segments grew 59%, not 31%. Meanwhile the company's own flat-$20-lithium scenario ($2.4-2.6B FY adjusted EBITDA) minus the $1,521.9M already banked in H1 implies a second half of $878M-$1,078M - down about 36% versus the first half at unchanged prices - while consensus FY revenue of $6,412M sits above the top of that entire scenario band.

THE CALL: HOLD (3/5, A GOOD COMPANY THAT IS A LEVERED CLAIM ON ONE COMMODITY PRICE) — base-case value ~$112.0 vs ~$125.42 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$112 vs $125.42 (-11%). Bull $207, base $111, bear $51. Street: Hold, avg target $206.75 - which IS our bull case.

- Sales $1,743.3M (+31.1%) vs $1,606.9M. Adj EPS $3.75 vs $3.20. Adj EBITDA $858.1M (+155%), 49.2% margin. FCF $638.3M. Net debt $245M, 0.5x.

- But 86% of the Energy Storage gain was PRICE ($19.53 vs $12.17/kg), not volume (+11%). ALB's own $20-lithium case implies H2 EBITDA -36%.

What to watch: UP: a Q3 where VOLUME rather than realized price carries the growth; H2 adjusted EBITDA beating the company's own implied ~$978M; Specialties adjusted EBITDA holding above $300M; lithium carbonate holding above $20/kg into the winter; the FY26 capex figure landing below $500M. DOWN: realized price rolling back toward the mid-teens; the Talison CGP3 ramp slipping further after the June 9 fire; CORFO commissions climbing; consensus cutting FY26 revenue back inside the $5.7-6.0B scenario band; any further half-over-half decline in Energy Storage adjusted EBITDA.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Nova Ltd (NVMI) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $254.958M, +15.9% y/y, the TOP of the $245-255M guide. Non-GAAP diluted EPS $2.51 vs a $2.41 bar. GAAP diluted EPS $2.20, up only 2.8% on net income that rose 9.8% (diluted shares +7.5%). Non-GAAP gross margin 58.1%, down from 60.0%. H1 operating cash flow $81.0M vs $114.2M, -29.1%. Receivables +38.4% since December; DSO 63 to 75 days; deferred revenue -31.6%. Q3 guide $277-287M revenue and $2.70-2.85 non-GAAP EPS - in line, not a raise. Print was BMO (6-K accepted 07:30 ET); the stock opened flat at $402.91 and closed $381.32, -5.23%.

Nova reported Q2 2026 before the open on August 6 and beat on both lines: record revenue of $255.0M, up 16%, and record non-GAAP EPS of $2.51 against a $2.41 bar. The stock fell 5.23%, while KLA, Camtek, Teradyne, Applied Materials and Onto barely moved - this was not a sector selloff. Inside Nova's own GAAP-to-non-GAAP reconciliation sits a line called "revaluation of operating lease liabilities and remeasurement of intercompany loans," a shekel FX item. In Q2 2025 it SUBTRACTED $6.955M from non-GAAP income; in Q2 2026 it ADDED $3.398M. That is a $10.353M swing, or $0.30 per diluted share, in one line of one table. Treat it identically in both years and this quarter earned $2.41 versus $2.41 a year ago - zero growth against a $2.41 Street bar. Underneath, first-half operating cash flow fell 29% while net income rose 8%, receivables jumped 38% since December on a 13% revenue line, and deferred revenue fell 32%. The Q3 guide of $277-287M and $2.70-2.85 is in line with the back-solved bar, not a raise. And the Q3 GAAP-to-non-GAAP bridge contains no currency line at all.

THE CALL: SELL (4/5, A GREAT BUSINESS AT A PRICE THAT NEEDS A DECADE TO GO RIGHT) — base-case value ~$220.0 vs ~$381.32 today.

KEY METRICS:

- CALL: SELL 4/5, fair value ~$220 vs $381.32 (-42%). Bull $329, base $213, bear $129. Street: Buy, avg target $579-603, no sells.

- Revenue $255.0M (+15.9%), top of the $245-255M guide. Non-GAAP EPS $2.51 vs $2.41. GAAP EPS $2.20, +2.8%. Non-GAAP gross margin 58.1% vs 60.0%.

- But: the FX add-back swung $10.4M. Like-for-like EPS $2.41 vs $2.41 - ZERO growth. H1 cash flow -29%. Receivables +38%. Q3 guide only in line.

What to watch: UP: operating cash flow converting back above 80% of net income; receivables returning toward 65 days; deferred revenue rebuilding; non-GAAP gross margin back to 60%; a Q4 guide that is a genuine raise rather than in line; the buyback switched back on. DOWN: another quarter where the FX revaluation line carries the beat; DSO past 80 days; the buyback still off while the diluted share count climbs; non-GAAP gross margin below 58%; any tightening of export rules against a book that was still 33% China in 2025; memory mix slipping further as 3D NAND stays muted.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Take-Two Interactive Software (TTWO) Q1 FY2027 — Q1 FY2027 (quarter ended June 30, 2026): net bookings $1,385.9M, DOWN 2.6% y/y, above the $1,320-1,370M guide. GAAP net revenue $1,533.9M (+2.0%). GAAP EPS -$0.18 vs a -$0.21 consensus. Management-basis EPS $0.35, computed off the company's own reconciliation. Gross margin 57.5%, down from 62.8%, including a $43.4M title impairment. Operating cash flow -$168.8M. Mobile bookings -6.7%, console +10.7%, PC -22.3%. FY2027 net bookings guide reiterated at $8.0-8.2B; EBITDA guide cut $18.5M at the midpoint; capex guide raised from ~$200M to ~$290M. GTA VI reaffirmed for November 19, 2026. Print was BMO (8-K accepted 07:37 ET); the stock opened $240.05, faded to $228.20, and sat at $232.47, -1.04%.

Take-Two reported fiscal Q1 2027 before the open on August 7 and nearly every screen showed the same thing: GAAP net revenue of $1,533.9M against a consensus of about $1,357.8M, a 13% beat. That comparison is a metric mismatch. Take-Two is guided and modelled on NET BOOKINGS, and net bookings were $1,385.9M - down 2.6% year on year. The proof is one line off the company's own May outlook: it guided GAAP revenue to $1,450-1,500M, so a $1,357.8M figure cannot be a revenue estimate; it sits inside the $1,320-1,370M bookings guide. Like for like the beat is 2.1%, and the $148.0M gap between revenue and bookings is deferred revenue released, with the deferred balance down $171.5M in ninety days. Underneath, the full-year bookings guide was reiterated at $8.0-8.2B while the EBITDA guide was quietly cut $18.5M at the midpoint and capital spending was raised 45%, from about $200M to about $290M.

THE CALL: SELL (3/5, A REAL GAME AT A PRICE THAT NEEDS TWO OF THEM) — base-case value ~$167.0 vs ~$232.47 today.

KEY METRICS:

- CALL: SELL 3/5, fair value ~$167 vs $232.47 (-28%). Bull $215, base $178, bear $95. Street: Buy, 57 analysts, avg target $291.

- Net bookings $1,385.9M, DOWN 2.6% (guide $1,320-1,370M). GAAP revenue $1,533.9M. GAAP EPS -$0.18 vs -$0.21 consensus. Mgmt-basis EPS $0.35.

- But: the $1.36B 'consensus' was a BOOKINGS bar, not revenue. Real beat +2.1%. FY27 EBITDA guide cut $18.5M; capex +45%. H2 must grow 52%.

What to watch: UP: an actual GTA VI pre-order unit figure disclosed on the record; mobile net bookings returning to growth; a December quarter that beats the back-half run rate the full-year guide implies; the capital spending guide coming back down; free cash flow turning positive earlier than guided. DOWN: any movement at all on the November 19 launch date; the full-year net bookings guide finally coming down; mobile bookings falling faster than 7%; another quarter where the headline guide is reiterated while the cash guidance is trimmed underneath it; gross margin below 57%.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Applied Optoelectronics (AAOI) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): revenue $191.9M, +86.4% y/y and +27.0% sequentially, a fifth straight record. Non-GAAP EPS $0.06 vs a ~$0.015 bar; GAAP EPS -$0.28 (net loss $22.8M). GAAP gross margin 27.7%, DOWN from 30.3% y/y and 29.1% q/q. Operating loss -$24.7M vs -$16.0M. Adjusted EBITDA -$0.5M. The 8-K was accepted 4:13 p.m. ET on Aug 6 (AMC), so the $124.22 Aug 6 close is the PRIOR close, not the reaction. Q3 guide $255-290M.

Applied Optoelectronics printed record Q2 2026 revenue of $191.9M, up 86%, and every outlet led with the same line: a return to non-GAAP profitability, $0.06 a share against a bar of about $0.015. Read the reconciliation table and more than half of that profit is one item - 'tax (benefit) expense related to the above', +$14.262M, worth $0.18 a share. Strip only that line and non-GAAP EPS is -$0.12. Actual GAAP income tax EXPENSE in the quarter was $1.3M, and a year ago the same add-back was $337K. The cross-check is on the same page: adjusted EBITDA was NEGATIVE $543K. Non-GAAP net income of $5.5M sitting above a negative EBITDA number is the tell. Underneath it, revenue rose 86% while the operating loss got 55% WORSE (-$24.7M vs -$16.0M), because gross profit of $53.2M does not cover operating expenses of $77.9M. First-half free cash flow was -$408.9M on $343.1M of revenue, funded by $968.1M of equity raised in six months. Top three customers are 92% of revenue.

THE CALL: SELL (3/5, A REAL RAMP AT A PRICE THAT NEEDS FOUR OF THEM) — base-case value ~$56.0 vs ~$124.22 today.

KEY METRICS:

- CALL: SELL 3/5, fair value ~$56 vs the $124.22 close (-55%). Bull $85, base $52, bear $11. Street: Buy, 16 analysts, avg target $160.

- Revenue $191.9M +86% (Datacenter $107.7M +140%, CATV $80.6M +44%). Non-GAAP EPS $0.06; GAAP -$0.28. Q3 guide $255-290M, +42% q/q.

- But: $14.3M tax add-back IS the profit (ex-tax: -$0.12). Adjusted EBITDA -$0.5M. Op loss -$24.7M vs -$16.0M. H1 FCF -$409M. Shares +43.7%.

What to watch: UP: gross margin above 32% as the 1.6T mix lands; operating expenses growing slower than revenue for two consecutive quarters; a December quarter that delivers the sequential step the full-year framing implies; free cash flow turning positive without another equity raise. DOWN: the September quarter landing at the low end of $255-290M; gross margin below 27% again; another capital raise before December; or the non-GAAP tax add-back reappearing as the only route to a reported profit.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.